证券代码：688626 证券简称：翔宇医疗 公告编号：2025-056 河南翔宇医疗设备股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 2、 公司在任监事3人，现场出席3人； 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 24 日 （二） 股东大会召开的地点：河南省安阳市内黄县帝喾大道中段公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 74 | | --- | --- | | 普通股股东人数 | 74 | | 2、出席会议的股东所持有的表决权数量 | 114,629,702 | | 普通股股东所持有表决权数量 | 114,629,702 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 73.4476 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 ...

Group 1 - The core viewpoint of the news is that Xiangyu Medical experienced a decline in stock price and trading volume on November 21, with a drop of 3.92% and a transaction amount of 60.05 million yuan [1] - On November 21, the financing buy-in amount for Xiangyu Medical was 4.97 million yuan, while the financing repayment was 6.06 million yuan, resulting in a net financing buy-in of -1.09 million yuan [1] - As of November 21, the total balance of margin trading for Xiangyu Medical was 160 million yuan, which accounts for 2.24% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Xiangyu Medical was 9,531, an increase of 51.24% compared to the previous period, while the average circulating shares per person decreased by 33.88% to 16,787 shares [2] - For the period from January to September 2025, Xiangyu Medical achieved an operating income of 537 million yuan, representing a year-on-year growth of 6.00%, but the net profit attributable to the parent company was 43.98 million yuan, a decrease of 40.09% year-on-year [2] - Since its A-share listing, Xiangyu Medical has distributed a total of 277 million yuan in dividends, with 157 million yuan distributed in the last three years [3]

Core Viewpoint - The increasing prevalence of chronic respiratory diseases in China, particularly among individuals over 40, is driving the demand for sputum suction machines, with a notable rise in procurement following the COVID-19 pandemic [1][8]. Market Overview - The total procurement of sputum suction machines in China reached 4,109 units in 2023, marking a year-on-year increase of 65.49%, with a total procurement value of 118 million yuan, up 43.90% [1][8]. - In 2024, the procurement volume is expected to decline to 3,154 units, with a total value of 89 million yuan and an average price of 28,200 yuan per unit [1][8]. Industry Development - Sputum suction machines have evolved from manual devices in the early 20th century to electric models in the 1950s, and further advancements have led to the introduction of ultrasonic technology and smart devices in the 21st century [3][4]. - The market for sputum suction machines is supported by government policies aimed at enhancing the medical device industry, which is considered a strategic emerging industry in China [5][6]. Industry Chain - The upstream of the sputum suction machine industry includes medical-grade plastics, rubber, motors, control systems, and sensors, while the midstream consists of manufacturing companies, and the downstream includes hospitals and rehabilitation centers [6][7]. - The demand for sputum suction machines is primarily driven by hospitals, especially top-tier hospitals where the configuration rate exceeds 90% [6]. Competitive Landscape - Domestic sputum suction machines have gained a significant market share, reaching 76.67% in 2024, while imported brands still hold a substantial position in the high-end market [8]. - The CR5 model of sputum suction machines holds a market share of 47.93%, with the leading brands being Heima, Pumen, and Siya [8]. Future Trends - Future developments in sputum suction machines are expected to include more sensors and smart algorithms for automatic parameter adjustments based on patient needs, as well as broader applications of IoT technology for remote monitoring and data transmission [12].

Core Insights - Brain-computer interface (BCI) technology has achieved a significant breakthrough in policy, with Shanghai Ladder Medical Technology Co., Ltd. announcing that its "implantable wireless brain-computer interface system" has entered the special review process for innovative medical devices by the National Medical Products Administration, marking a transition from laboratory to clinical application [1] - Interest in companies related to brain-computer interfaces has surged, with over ten brokerages and several investment funds conducting joint research on Xiangyu Medical [1] Company Developments - Xiangyu Medical reported a total R&D investment of 49.0947 million yuan in the third quarter, representing a year-on-year increase of 27.67%, with approximately 60%-70% allocated to brain-computer interface-related fields [2] - The company has established strategic partnerships with over 260 large hospitals to develop brain-computer interface treatment centers and research-oriented wards, aiming to cover 500 top-tier hospitals by the Spring Festival and expand to over 1,000 hospitals next year, with progress ahead of expectations [2] - Xiangyu Medical's innovative products, including those utilizing brain-computer interface technology, present new opportunities for collaboration with high-level hospitals, enhancing the company's brand positioning and influence in the high-end hospital market [2]

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-054 河南翔宇医疗设备股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届监事会第八次会议于2025年11月14日在公司 会议室以现场结合通讯的方式召开。会议通知于同日送达各位监事，全体监事一致同意豁免本次会议通 知时间要求。本次会议应出席监事3人，实际出席监事3人。会议由监事会主席李治锋先生主持。会议的 召开及表决程序符合有关法律、行政法规、部门规章和《公司章程》的规定。 二、监事会会议审议情况 经与会监事投票表决，本次会议审议并通过了以下议案： （一）审议通过《关于为全资子公司提供担保的议案》 经审议，监事会认为：公司本次为全资子公司提供担保，是为了满足全资子公司建设发展规划和实际生 产经营的资金需求，符合公司经营发展需要；该担保对象为公司全资子公司，担保风险可控，不会损害 公司利益；本次担保事项符合法律法规及《公司章程》的有关规定。 ...

Group 1 - The core announcement is that Xiangyu Medical has approved a proposal to provide guarantees for its wholly-owned subsidiary, Henan Ruibeta Medical Technology Co., Ltd. [1] - The subsidiary, Ruibeta, plans to apply for a loan not exceeding RMB 400 million from financial institutions for its development and operational needs [1] - The company intends to provide an irrevocable joint liability guarantee for the total amount of up to RMB 400 million without any counter-guarantee [1]

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-055 河南翔宇医疗设备股份有限公司 根据河南翔宇医疗设备股份有限公司（以下简称"公司"）全资子公司河南 瑞贝塔医疗科技有限公司（以下简称"瑞贝塔"）的建设发展规划和实际生产经 营需要，瑞贝塔计划向金融机构申请总额不超过人民币 40,000.00 万元的贷款。 公司拟为瑞贝塔提供担保总额度不超过 40,000.00 万元的不可撤销连带责任担 保，具体条款届时以签订的合同为准。本次担保无反担保。 | | 被担保人名称 | | 河南瑞贝塔医疗科技有限公司 | | --- | --- | --- | --- | | | 本次担保金额 | 40,000.00 万元 | | | 担保对象 | 实际为其提供的担保余额 | 0.00 万元 | | | | 是否在前期预计额度内 | 是 □否 | ☑不适用：_________ | | | 本次担保是否有反担保 | 是 ☑否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股 | | | 子公司对 ...

河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届监事会第八次 会议于 2025 年 11 月 14 日在公司会议室以现场结合通讯的方式召开。会议通知 于同日送达各位监事，全体监事一致同意豁免本次会议通知时间要求。本次会议 应出席监事 3 人，实际出席监事 3 人。会议由监事会主席李治锋先生主持。会议 的召开及表决程序符合有关法律、行政法规、部门规章和《公司章程》的规定。 二、监事会会议审议情况 经与会监事投票表决，本次会议审议并通过了以下议案： （一）审议通过《关于为全资子公司提供担保的议案》 经审议，监事会认为：公司本次为全资子公司提供担保，是为了满足全资子 公司建设发展规划和实际生产经营的资金需求，符合公司经营发展需要；该担保 对象为公司全资子公司，担保风险可控，不会损害公司利益；本次担保事项符合 法律法规及《公司章程》的有关规定。 证券代码：688626 证券简称：翔宇医疗 公告编号：2025-054 河南翔宇医疗设备股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ...

河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688626 证券简称：翔宇医疗 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 11 月 1 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议资料 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议须知 河南翔宇医疗设备股份有限公司（以下简称"公司"）为维护全体股东的合 法权益，保证股东大会的正常秩序和议事效率，确保大会的顺利进行，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股东大会规则》及《公司章程》、《股 东大会议事规则》及中国证券监督管理委员会、上海证券交易所的有关规定，公 司特制定本会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务请 出席大会的股东或其代理人或其他出席者准时到达会场签到确认参会资格。会议 开始后，会议登记应当终 ...

Core Insights - The brain engineering sector is leading the market with a rise of 1.05% [1] Company Performance - Aipeng Medical saw a significant increase of 7.51% [1] - Innovation Medical experienced a rise of 4.41% [1] - Century Huatong increased by 3.41% [1] - Chengyitong, Xiangyu Medical, and Sanbo Brain Science all rose by over 2% [1]